What’s up with the drug channel? Julie Yoo, a general partner at a16z Bio+Health, joins Adam Fein, the CEO of Drug Channels Institute, and Olivia Webb, the editorial lead for a16z Bio+Health, to discuss this question. We talk about PBMs, the 340B drug program, some of the startups working within and around the primary drug channel, and whether there’s room for entrepreneurs to build in such a consolidated space.
For additional reading, see some of Adam’s work on his blog, Drug Channels:
The Science and Supply of GLP-1s with Carolyn Jasik
The Intersection of Biotech x High Tech with Vineeta Agarwala
AI in Pharmaceutical R&D with Kim Branson
Unleashing CAR T with Carl June
Longevity as a Health Asset with Tom Hale
The Power of Drug Discovery with Philip Tagari
AI-Enabled Continuity of Care with Ed and Todd Park
Grand Challenges in Healthcare AI with Vijay Pande and Julie Yoo
Adapting Biopharma to AI with Greg Meyers
Behind the Buy: Payors and Providers on AI Adoption
Biotech Revolution with Software Engineering Daily
Dark Genome Hunting with Rosana Kapeller and Marty Taylor
DNA as Data Storage with Vijay Pande
The Most Interesting Healthcare Companies You've Never Heard Of with Julie Klapstein
CRISPR by Design with Benjamin Oakes
Metrics for a Complex Machine with Josh Clemente
Transitioning From Gymnast to Investor with Aly Raisman
Finding PMF in Healthcare (After Tasting it Elsewhere) with Eren Bali and Max Cohen
IRA, AI Regulation, and the Future with Joe Grogan
Drag & Drop Genome Editing
Create your
podcast in
minutes
It is Free